Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Discovery of VU0467319: an M Positive Allosteric Modulator Candidate That Advanced into Clinical Trials.
ACS Chem Neurosci
December 2024
Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Herein we detail the of VU0467319 (VU319), an M Positive Allosteric Modulator (PAM) clinical candidate that successfully completed a Phase I Single Ascending Dose (SAD) clinical trial. VU319 () is a moderately potent M PAM (M PAM EC = 492 nM ± 2.9 nM, 71.
View Article and Find Full Text PDFInfluence of vascular graft type for ascending aorta replacement on the early postoperative outcome.
Perfusion
October 2024
Department of Cardiothoracic Surgery, University Hospital Cologne, University of Cologne, Cologne, Germany.
Article Synopsis
- The study aimed to determine if the type of vascular graft used during isolated ascending aortic surgery affects early postoperative outcomes like bleeding rates, blood product usage, and need for re-thoracotomy.
- It included 46 patients, analyzing two types of grafts: collagen impregnated polyester (Hemashield) and gelatin impregnated woven fabric (Gelweave), with various underlying aortic conditions.
- Results showed no significant differences between the two graft types in terms of bleeding volume, blood product consumption, re-thoracotomy rates, 30-day mortality, or stroke incidence.
Classification, angioarchitecture and treatment outcomes of medullary bridging vein-draining dural arteriovenous fistulas in the foramen magnum region: a multicenter study.
Neuroradiology
October 2024
Department of Neurosurgery, National Hospital Organization, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan.
Article Synopsis
- The study aimed to classify medullary bridging vein-draining dural arteriovenous fistulas (MBV-DAVFs) near the foramen magnum and analyze their structure and treatment outcomes.
- It categorized these fistulas into four groups: JV-BV (jugular vein proximity), ACV-BV (anterior condylar vein), MS-BV (marginal sinus), and SCS-BV (suboccipital cavernous sinus), and observed a male predominance among patients.
- Results showed varying treatment success rates with transarterial embolization (TAE) - complete obliteration was highest in the JV-BV group and lowest in the SCS-BV group, highlighting treatment challenges
Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.
Glob Health Res Policy
October 2024
School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 Dongdansantiao, Dongcheng District, Beijing, China.
Article Synopsis
- The study examines the growth of biosimilars in China, focusing on trastuzumab, aiming to understand its national uptake and the influencing factors.
- Utilizing interrupted time series analysis and a latent class trajectory model, the research analyzes data from March 2018 to February 2023, revealing trends in biosimilar and originator consumption post-introduction of the first biosimilar.
- Findings indicate a moderate national biosimilar penetration of 27% by February 2023, with faster uptake in regions with specific socioeconomic characteristics, such as better insurance coverage and lower GDP per capita.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!